TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03587701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)
Description: pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe (Period 1)
Description: pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection (Period 1)
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during first 42 days of treatment (Period 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)
Description: pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra 100Mg/0.67Ml Inj Syringe (Period 2)
Description: pre-filled syringes of anakinra 100mg/0.67mg will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection (Period 2)
Description: pre-filled matching placebo injections will be provided and will be self-administered by patients daily during next 42 days of treatment (Period 2)
Study: NCT03549676

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: For patients who do not respond or partial respond for first time FMT treatment, a second time FMT treatment using different donor should be considered.
Study: NCT01519791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.~Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50.
Study: NCT01681225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High PEEP mechanical ventilation
Study: NCT04085809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmLactin® Rapid Relief
Description: AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AmLactin® Rapid Relief
Description: AmLactin® Rapid Relief, BID application for 14 days. AmLactin is an over-the-counter cosmetic.
Study: NCT01997216

Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lens
Description: Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines

Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lens
Description: Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
Study: NCT02933255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/F
Description: PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/F
Description: PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10\^8 infectious units. PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10\^9 infectious units.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is to be administered as a flat dose over approximately 30-minutes via intravenous (IV) infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Participants in the neoadjuvant cohort will undergo a radical prostatectomy in week 9. (If surgery is scheduled earlier than 9 weeks after initial dosing, the 6 and 8 week dosing may be skipped, and surgery may be done as early as week 5.)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: A baseline biopsy is performed for participants in the neoadjuvant cohort that do not have a previous collection of biopsy material.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Participants who experience aches or fever after vaccination may take Tylenol as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Participants who experience aches or fever after vaccination may take Tylenol as directed.
Study: NCT02538965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Participants will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
Study: NCT03361774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride).
Description: Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 5% w/w KNO3 and 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth.~Participants will be permitted to rinse with tap water post-brushing if they wish to.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride).
Description: Participants will be instructed to dose the toothbrush with a strip of dentifrice containing 0.454% w/w SnF2 (1100 ppm fluoride) (a full brush head) and brush for at least 1 timed minute, twice daily (morning and evening), making sure to brush all sensitive areas of their teeth. Participants will be permitted to rinse with tap water post-brushing if they wish to.
Study: NCT01892280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teenwork intervention
Description: Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teenwork intervention
Description: Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text message reminders to check blood glucose levels at self-selected times

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text message reminders
Description: Text message reminders to check blood glucose levels at self-selected times
Study: NCT02079779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic-assisted therapy
Description: The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical therapy
Description: Conventional therapy will be performed by therapists specialized in neuro-rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical therapy
Description: Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
Study: NCT04322565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Cochicine 1mg/day
Study: NCT01467986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
Study: NCT01519791

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
Study: NCT03975829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: dabrafenib oral, twice daily
Study: NCT01467986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).~Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed
Study: NCT02002286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii Hook F extract (TwHF extract)
Description: The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.

Intervention type: DRUG
Group type: OTHER
Intervention: cART
Description: Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
Study: NCT04471129

Intervention type: OTHER
Group type: OTHER
Intervention: HFO/O2C/NIV
Description: High-flow oxygen therapy + O2C + Non invasive ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: NIV/O2C/HFO
Description: Non invasive ventilation + O2C + High-flow oxygen therapy
Study: NCT03020537

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone
Description: Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
Study: NCT03975829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametinib oral, once daily
Study: NCT01814553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Daily treatment starting 40 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Daily treatment starting 40 mg per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide
Description: Follow cohort assignment and diarrhea management guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loperamide
Description: Follow cohort assignment and diarrhea management guidelines
Study: NCT01864395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Centrifugation Method
Description: Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online MUF
Description: Hemofilter is used online while the heart-lung machine is connected to the patient.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Offline MUF
Description: Hemofilter is used offline when the heart-lung machine is not connected to the patient.
Study: NCT00599963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 1 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: paricalcitol 1 mg/day
Study: NCT04623086

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Degludec
Description: Insulin Degludec injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Degludec
Description: Insulin Degludec injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Insulin Glargine injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9g/L sodium chloride (normal saline) subcutaneous injection manufactured to mimic insulin glargine injection
Study: NCT03833401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous tissue transplantation
Description: Root canal disinfection and revascularization with patient's own minced pulp tissues

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Root canal revascularization
Description: Root canal disinfection and revascularization without tissue transplantation
Study: NCT03747510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CarpX Device
Description: Transverse carpal ligament release with CarpX Device
Study: NCT02695537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
Study: NCT03239223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-1968
Description: Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
Study: NCT04820660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task orientated strengthening training
Description: 1. Standing and reaching in different directions for objects located beyond arm's length to promote loading of the lower limbs and activation of lower limb muscles;~2. Sit-to-stand from various chair heights to strengthen the lower limb extensor muscles;~3. Stepping forward and backward onto blocks of various heights to strengthen the lower limb muscles;~4. Stepping sideways onto blocks of various heights to strengthen the lower limb muscles;~5. forward step-up onto blocks of various heights to strengthen the lower limb muscles;~6. heel(s) raise and lower while maintaining in a standing posture to strengthen the plantar- flexor muscles.~Each workstation was 5 min in duration for each exercise class. Each subject participated in a one-to-one therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training exercises
Description: 1. Stepping forward, backward, and sideways on the exercise step;~2. Stepping over blocks of various heights;~3. Standing up from a chair, walking four steps forward, performing a bilateral stool touch and walking backwards to the chair;~4. Standing up from a chair, walking four steps forward, turning to the right, stepping over the exercise step, turning to the right again and walking forwards to the chair (repeat the exercise circuit in opposite direction);~5. From a sitting position on a 65-cm Swiss ball, performing a range of motion and balance exercises (forward and backward rolling of the~6. Arms; bending the trunk forward and side to side);~7. Performing double-legged stance for 10 s;~8. Performing tandem stance for 10 s;~9. Rising from a chair without the use of the arms;~10. Walking forward and backward with a tandem walking pattern (toes of one foot touching the heel of the foot in front);~11. Performing single- legged stance for 10 s.
Study: NCT04207463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK105
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1. AK105 has a typical antibody structure and is composed of two lgG1 subtype heavy chains and two kappa subtypes light chains covalently linked by disulfide bonds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor
Study: NCT04086407

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual-axis inclinometer attached to the subject's forehead with tape
Description: This is the first clinical trial in the industry to address OSA symptom severity and snoring as a direct function of head pitch and roll angle. The head pitch and roll angle can be used with high consistency to predict OSA symptom severity. The apnea equation is based on the gravitational crush forces of the mass of the tongue and nearby tissue on the upper air way and is valid for most OSA sufferers.
Study: NCT00482586

Intervention type: OTHER
Intervention: medical chart review
Description: Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.

Intervention type: OTHER
Intervention: questionnaire administration
Description: Patients with hepatic neoplasms who undergo Image-guided Therapy

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Description: Patients with hepatic neoplasms who undergo Image-guided Therapy
Study: NCT03263975

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade or Enterade
Description: Commercially available oral rehydration therapies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gatorade or Enterade
Description: Commercially available oral rehydration therapies
Study: NCT03430765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Single 2-hour individual Acceptance and Commitment Therapy coping skills session.
Study: NCT04522115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercises
Description: Group(1) aerobic training: Each exercise training session included 3 to 5 minutes of warm-up, range-of-motion exercises, interval training(aerobic training), cool-down, and post-exercise range-of-motion exercises. Patients exercise at 40 to 60% of maximum heart rate.~Group(2) resistance exercise: training of the lower extremities was performed three times per week. Starting weights for knee extension and hip abduction and flexion were determined from a three-repetition maximum (3RM) using ankle weights that can be adjusted in 1 lb. increments. A 3RM is the maximum weight that can be lifted three times with proper technique. Training started at approximately 60% of 3RM for two sets of 10 repetitions and was increased to three sets as tolerated.
Study: NCT04228016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: nastent™
Description: Patients with Nasal obstruction at night, will be used intrasal stent during 15 nights. These are flexible silicone tubes that are lubricated and easy to insert into the nasal cavities, which would restore the permeability of the nasal cavities.
Study: NCT00109408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: 7.5-20mg po weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8mg/kg iv every 4 weeks